View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Dec. 31, 2012	Jan. 31, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	Biota Pharmaceuticals, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		28,352,329
Amendment Flag	false
Entity Central Index Key	0000072444
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2012
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Dec. 31, 2012	Jun. 30, 2012
Current assets
Cash and cash equivalents	$ 74,111	$ 53,790
Accounts receivable	11,383	5,966
Prepaid and other current assets	2,495	1,374
Total current assets	87,989	61,130
Non-current assets:
Property and equipment, net	4,454	4,944
Intangible assets, net	1,312	1,804
Deferred tax assets	2,427	1,419
Total non-current assets	8,193	8,167
Total assets	96,182	69,297
Current liabilities:
Accounts payable	4,466	2,851
Accrued expenses	5,649	6,133
Accrued severance obligations	4,423
Deferred revenue	881	398
Deferred tax liabilities	1,526	130
Total current liabilities	16,945	9,512
Non-current liabilities:
Other liabilities, net of current portion	275	504
Total non-current liabilities	275	504
Total liabilities	17,220	10,016
Stockholders’ equity:
Common stock, $0.10 par value; 200,000,000 shares authorized 34,219,690 shares issued and 182,350,316 shares outstanding at December 31, 2012 and June 30, 2012, respectively	3,422	100,394
Additional paid-in capital	234,384	668
Treasury stock, 5,867,361 and 1,816,178 at cost, at December 31, 2012 and June 30, 2012, respectively	(117,048)	(1,397)
Accumulated other comprehensive income	30,517	29,516
Accumulated deficit	(72,313)	(69,900)
Total stockholders’ equity	78,962	59,281
Total liabilities and stockholders’ equity	$ 96,182	$ 69,297

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2012	Jun. 30, 2012
Common Stock, Par value (in Dollars per share) (in Dollars per share)	$ 0.10	$ 0
Shares Authorized (in Shares)	200,000,000	0
Shares Issued (in Shares)	34,219,690	182,350,316
Common stock, shares outstanding (in Shares)	28,352,329	182,350,316
Treasury stock, shares, at cost (in Shares)	5,867,361	1,816,178

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
Revenue:
Royalty revenue and milestones	$ 1,943	$ (1,047)	$ 1,927	$ 1,460
Revenue from services	8,208	3,121	9,681	4,732
Other	235	19	242	47
Total revenue	10,386	2,093	11,850	6,239
Operating expense:
Cost of revenue	7,088	2,929	8,637	4,260
Research and development	4,046	5,727	8,647	12,056
General and administrative	7,077	1,853	10,268	3,651
Total operating expense	18,211	10,509	27,552	19,967
Loss from operations	(7,825)	(8,416)	(15,702)	(13,728)
Non-operating income:
Gain recorded on merger	7,805		7,805
Research and development credit	4,428		4,428
Interest income	415	841	952	1,826
Income (loss) before tax	4,823	(7,575)	(2,517)	(11,902)
Income tax benefit	6	520	104	650
Net Income (Loss)	$ 4,829	$ (7,055)	$ (2,413)	$ (11,252)
Basic income (loss) per share (in Dollars per share)	$ 0.17	$ (0.31)	$ (0.09)	$ (0.50)
Diluted income (loss) per share (in Dollars per share)	$ 0.17	$ (0.31)	$ (0.09)	$ (0.50)
Basic weighted-average shares outstanding (in Shares)	28,137,346	22,695,081	28,137,346	22,695,081
Diluted weighted-average shares outstanding (in Shares)	28,352,329	22,695,081	28,137,346	22,695,081
Comprehensive income (loss):
Exchange differences on translation of foreign operations, net of tax	$ (285)	$ 3,006	$ 1,001	$ (3,066)
Total comprehensive income (loss)	$ 4,544	$ (4,049)	$ (1,412)	$ (14,318)

Condensed Statements of Stockholders’ Equity and Comprehensive Income - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Translation Adjustment [Member]	Total
Balance at Jun. 30, 2011	$ 99,805	$ 740	$ (968)	$ (50,705)	$ 32,556	$ 81,428
Balance (in Shares) at Jun. 30, 2011	181,417,556		(1,311,034)
Comprehensive income
Exchange differences on translation of foreign operations					(3,066)	(3,066)
Net loss				(11,252)		(11,252)
Total Comprehensive income						(14,318)
New shares issued on exercise of options	$ 353	(353)
New shares issued on exercise of options (in Shares)	232,155
Share-based compensation		279				279
Balance at Dec. 31, 2011	$ 100,158	666	$ (968)	(61,957)	29,490	67,389
Balance (in Shares) at Dec. 31, 2011	181,703,711		(1,311,034)
Balance at Jun. 30, 2012	$ 100,394	668	$ (1,397)	(69,900)	29,516	$ 59,281
Balance (in Shares) at Jun. 30, 2012	182,350,316		(1,816,178)			182,350,316
Comprehensive income
New shares issued on vesting of options on merger	$ 1,118	(1,118)
Acquisition of Nabi Biopharmaceuticals (in Shares)	(153,398,048)		(4,051,183)			0.1249539870
Restricted stock units, net	$ 21	(21)
Restricted stock units, net (in Shares)	214,983
Comprehensive income
Exchange differences on translation of foreign operations					1,001	$ 1,001
Net loss				(2,413)		(2,413)
Total Comprehensive income						(1,412)
New shares issued on exercise of options	$ 410	(410)
New shares issued on exercise of options (in Shares)	413,335
Share-based compensation		1,898				1,898
Balance at Dec. 31, 2012	$ 3,422	234,384	$ (117,048)	$ (72,313)	$ 30,517	$ 78,962
Balance (in Shares) at Dec. 31, 2012	34,219,690		(5,867,361)			34,219,690
Comprehensive income
New shares issued on vesting of options on merger (in Shares)	4,639,104
Acquisition of Nabi Biopharmaceuticals	$ (98,521)	$ 233,367	$ (115,651)			$ 19,195

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net loss	$ (2,413)	$ (11,252)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,542	1,517
Share-based compensation	1,898	279
Gain recorded on merger	(7,805)
Change in operating assets and liabilities (net of liabilities acquired):
Accounts receivables	(5,392)	(3,214)
Prepaid expenses and other current assets	(1,116)	(121)
Deferred tax assets	390	(649)
Deferred revenue	485	353
Accounts payable and accrued expenses	192	77
Accrued severance obligations	(522)
Net cash used in operating activities	(12,741)	(13,010)
Cash flows from investing activities:
Cash acquired on merger	32,687
Purchases of property and equipment	(405)	(859)
Net cash provided by (used in) investing activities	32,282	(859)
Increase (decrease) in cash and cash equivalents	19,541	(13,869)
Cash and cash equivalent at beginning of period	53,790	74,177
Effects of exchange rate movements on cash and cash equivalents	780	(2,785)
Cash and cash equivalents at end of period	74,111	$ 57,523
Supplemental cash flow disclosure:
Proceeds from the issuance of common stock on merger	27,000
Proceeds to settle accrued severance obligations and other accrued liabilities on merger	$ 5,687

Note 1 - Company Overview

6 Months Ended

Dec. 31, 2012

Nature of Operations [Text Block]

(1) Company Overview

Biota Pharmaceuticals, Inc., together with its wholly owned subsidiaries (“Biota”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of innovative anti-infective products to prevent and treat a number of serious and potentially life-threatening viral and bacterial infectious diseases. The Company has been incorporated in the state of Delaware since 1969 and the corporate headquarters are located in Rockville, Maryland. On November 8, 2012, Nabi Biopharmaceuticals (“Nabi”) merged with Biota Holdings Limited, which was previously listed on the Australian Stock Exchange (ASX:BTA), and the resulting company was renamed to Biota Pharmaceuticals, Inc.

The Company is currently focused on developing oral, small molecule compounds to treat a number of infections, with its most advanced programs being directed toward respiratory diseases, including those caused by influenza A and B, human rhinovirus (“HRV”) and respiratory syncytial virus (“RSV”). In addition, it has research programs directed toward developing products to treat infections caused by hepatitis C virus (“HCV”) and a broad spectrum of gram positive and gram negative bacterial infections.

The Company has developed a neuraminidase inhibitor, zanamivir, which is marketed worldwide by GlaxoSmithKline (“GSK”) as Relenza™ for the prevention and treatment of influenza under a research and license agreement entered into with the Company in 1990. In addition, the Company co-owns a number of second-generation long-acting neuraminidase inhibitors (“LANI’s”) with Daiichi Sankyo, of which the lead product, laninamivir octanoate, was developed and is being marketed by Daiichi Sankyo as Inavir® Dry Powder Inhaler (“Inavir®”) in Japan for the treatment of influenza A & B infections in adults and children. In November 2012, Daiichi Sankyo submitted an application for a label change in Japan to manufacture and market the influenza antiviral product Inavir® for the prevention of influenza infection. The Company has filed an Investigational New Drug application (“IND”) with the United States Food and Drug Administration (“FDA”) to develop laninamivir octanoate, and in 2011 entered into a $231 million contract with the U.S. Office of Biomedical Advanced Research and Development Authority (“BARDA”) designed to provide up to $231 million for the completion of clinical development and United States (“U.S.”) based manufacturing of laninamivir octanoate for the treatment of influenza A and B infections.

Although several of the Company’s influenza products have been successfully developed and commercialized by other larger pharmaceutical companies under license agreements, the Company has not received regulatory approval for any product candidates it has developed independently, and does not have any commercialization capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any of its existing or future development-stage product candidates.

Merger between Nabi Biopharmaceuticals and Biota Holdings Limited

On November 8, 2012, Nabi and Biota Holdings Limited completed a merger (the “Merger”), and renamed the resulting company Biota Pharmaceuticals, Inc. Former Biota Holdings Limited shareholders retained approximately 83% of the Company’s shares of common stock, while former Nabi shareholders retained approximately 17% as consideration for Nabi’s net assets, the vast majority of which was $27 million in net cash on hand on the date of the transaction. As Nabi had minimal ongoing activity with respect to its development programs and related operations at the time of the merger, the Company’s future operations will be largely represented by the operations of Biota Holdings Limited. Further, due to the fact that former Biota Holdings Limited shareholders held a significant majority of the voting interest in the Company upon the completion of the merger, the merger has been accounted for as a “reverse merger”, such that, notwithstanding the fact that Nabi was the legal acquirer, Biota Holdings Limited is considered the accounting acquirer for financial reporting purposes. Accordingly, the financial statements of Biota Holdings Limited are treated as the historical financial statements of the Company, with the operating results of Nabi being included from November 8, 2012. As a result of the reverse merger, historical common stock amounts and additional paid-in capital have been adjusted. See Note 7 for additional discussion of the merger.

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies

6 Months Ended

Dec. 31, 2012

Basis of Presentation and Significant Accounting Policies [Text Block]

(2) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of the Company’s management, all material adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Certain information and footnotes disclosure normally included in the financial statements prepared in accordance with generally accepted accounting principles in the U.S. (U.S. GAAP) have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (‘SEC’). However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements included in our Form 8-K/A filed on January 23, 2013.

The period-end condensed consolidated balance sheet data were derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.

For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the year ended June 30, 2012 included in the Company’s Form 8-K/A that was filed with the SEC on January 23, 2013.

Summary of Significant Accounting Policies

Principles of Consolidation and Presentation

The condensed consolidated financial statements include the financial statements of Biota Pharmaceuticals, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. The Company’s fiscal year ends on June 30.

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of property and equipment, intangible assets, deferred income taxes, and obligations related to employee benefits. Actual results could differ from those estimates.

Recent Accounting Standards

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income. The new guidance allows an entity to present components of net income and other comprehensive income in one continuous statement, referred to as the statement of comprehensive income, or in two separate, but consecutive statements. The guidance eliminates the current option to report other comprehensive income and its components in the statement of changes in stockholders’ equity. While the new guidance changes the presentation of comprehensive income, there are no changes to the components that are recognized in net income or other comprehensive income under current accounting guidance. The Company adopted the provisions of ASU 2011-05 in the first quarter of 2012, and has presented a single statement of comprehensive income.

In May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRS). This ASU is intended to result in convergence between U.S. GAAP and IFRS requirements for measurement of and disclosures about fair value. The guidance amends current fair value measurement and disclosure guidance to include increased transparency around valuation inputs and investment categorization. The Company adopted the provisions of ASU 2011-04 in the first quarter of 2012. Adoption of the new guidance did not have an impact on the Company’s consolidated financial statements.

In December 2011, the FASB issued ASU 2011-11, which amended the disclosure requirements regarding offsetting assets and liabilities of derivatives, sale and repurchase agreements, reverse sale and repurchase agreements, and securities borrowing and securities lending arrangements. The enhanced disclosures will require entities to provide both net and gross information for these assets and liabilities. The amendment is effective for fiscal years beginning on or after January 1, 2013. The Company does not anticipate that this amendment will have a material impact on its consolidated financial statements.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less to be cash equivalents.

Short-Term Investments

Short-term investments constitute all highly liquid investments with term to maturity from three months to 12 months. The carrying amount of short-term investments is equivalent to its fair value. The Company did not have any short-term investments at December 31, 2012 and June 30, 2012.

Concentration of Credit Risk and Other Risks and Uncertainties

Cash and accounts receivable consists of financial instruments that potentially subject the Company to concentration of credit risk to the extent of the amount recorded on the balance sheet. The Company’s cash is invested with several large commercial banks located in the U.S. and Australia. The Company is exposed to credit risk in the event of default by one or more of the banks holding its cash or cash equivalents. The Company’s investment policies and procedures are reviewed periodically by management and its audit committee to monitor credit risk.

Derivative Instruments and Hedging Activities

Derivative financial instruments

The Company may use derivative financial instruments from time-to-time to hedge its exposure to foreign exchange arising from operating, investing and financing activities. The Company does not hold or issue derivative financial instruments for trading purposes; however, derivatives that do not qualify for hedge accounting are accounted for as trading instruments.

Derivative financial instruments are recognized initially at fair value. Subsequent to initial recognition, derivative financial instruments are stated at fair value. The gain or loss on re-measurement to fair value is recognized immediately in the consolidated statement of operations. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged.

Cash flow hedges

Exposure to foreign exchange risks arises in the normal course of the Company’s business and it is the Company’s policy to hedge anticipated sales and purchases in foreign currencies. The amount of hedging activity used is in accordance with approved policy and internal forecasts.

Where a derivative financial instrument is designated as a hedge of the variability in cash flows of a recognized asset or liability, or a highly probable forecast transaction, the effective part of any unrealized gain or loss on the derivative financial instrument is recognized directly in stockholders’ equity. When the forecast transaction subsequently results in the recognition of a non-financial asset or non-financial liability, the associated cumulative gain or loss is removed from stockholders’ equity and included in the initial cost or other carrying amount of the non-financial asset or liability.

For cash flow hedges, other than those covered by the preceding statement, the associated cumulative gain or loss is removed from stockholders’ equity and recognized in the consolidated statement of operations in the same period or periods during which the hedged forecast transaction affects the consolidated statement of operations and on the same line item as that hedged forecast transaction. The ineffective part of any gain or loss is recognized immediately in the consolidated statement of operations.

When a hedging instrument expires or is sold, terminated or exercised, or the Company revokes designation of the hedge relationship but the hedged forecast transaction is still probable to occur, the cumulative gain or loss at that point remains in stockholders’ equity and is recognized in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, then the cumulative unrealized gain or loss recognized in stockholders’ equity is recognized immediately in the consolidated statements of operations.

Receivables

Accounts receivable are recorded at the invoiced amount. An allowance for doubtful accounts is estimated based on probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded in the consolidated statement of operations. An allowance for uncollectible accounts receivable is estimated based on a combination of default history, aging analysis and any specific, known troubled accounts. When a receivable is finally established as uncollectible, it is written off against the allowance account for accounts receivables.

Property and Equipment

Property and equipment are recorded at acquisition cost, net of accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is three to 10 years. Leasehold improvements are amortized on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred.

Intangible Assets

Intangible assets generally consist of two elements:

Royalty prepayments

Royalty prepayments represent expenditures made to research institutions where the parties agreed to exchange future variable royalty payments in relation to intellectual property for a fixed payment. These prepayments have a finite useful life, usually being the expiration of the underlying patent or contract, and are carried at the present value of costs at acquisition date, less accumulated amortization. Amortization is based on the anticipated usage of the asset, determined with reference to expected sales of the related product over the contract or patent life.

Computer software

Costs incurred in acquiring software and licenses that are expected to provide future period financial benefits are capitalized to computer software. Amortization is calculated on a straight-line basis over periods ranging from one to three years.

Leased Assets

The Company accounts for its leases at their inception as either an operating or capital lease, depending on certain defined criteria. All of the Company’s leases in effect at December 31, 2012 and June 30, 2012 are considered operating leases. The costs of operating leases are charged to the consolidated statement of operations on a straight-line basis over the lease term. Additionally, any incentives we receive are treated as a reduction of our costs over the term of the agreement. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the life of the lease, without assuming renewal features, if any, are exercised.

Impairment of Long-lived Assets

The Company reviews its tangible and intangible assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing an impairment review, the Company estimates undiscounted cash flows from products that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value.

Severance Obligations and Employee Benefits

As a result of the purchase consideration and net assets acquired pursuant to the merger (see Note 7 to the consolidated financial statements), the Company recorded a $5.0 million accrual for severance obligations and employee benefits related to certain key officers and employees of Nabi upon completion of the merger. This accrual is classified as a current liability on the condensed consolidated balance sheet.

Research and Development Expense

Research and development expense includes, but is not limited to, the costs of activities associated with: drug discovery, such as medicinal chemistry, virology, microbiology, and biochemistry; drug target discover, such as molecular biology and modeling and structural biology; professional fees paid to third-party service providers in connection with conducting preclinical studies and treating patients enrolled in clinical trials and monitoring, accumulating and evaluating the related data; salaries and personnel-related expenses for our internal staff, including benefits and share-based compensation; the cost to develop, formulate and manufacture product candidates; legal fees associated with patents and intellectual property; consulting fees; license and sponsored research fees paid to third parties; and specialized information systems, depreciation and laboratory facility costs. Research and development costs do not include an allocation of any general and administrative expense. Research and development expenses are expensed as incurred.

The Company has received reimbursement for certain research and development activities pursuant to collaborations with other corporate entities, as well as for services performed pursuant to government grants and contracts, which the Company records as revenues in its consolidated statement of operations.

Income Taxes

The Company applies ASC 740 – Income Taxes, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Where the Company determines that it is more likely than not that some portion or all of the deferred tax assets will not be realized in the future, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that the Company determines is more likely than not to be realized.

Revenue Recognition

Revenue consists primarily of royalty payments, license fees, milestone payments, payments for services performed pursuant to government grants and contracts as well as certain research and development activities pursuant to collaborations with other corporate entities.

Revenue from royalties is recognized upon sales of the underlying product by the relevant third party. The Company generally receives written confirmation of the amount of royalty revenue from its licensees’ on a quarterly basis.

Revenue for services performed pursuant to contract or grants is recognized as revenue when earned, typically when the underlying services or activities are rendered. The Company analyzes cost reimbursable grants and contracts to determine whether it should report such reimbursements as revenue, or as an offset to the related research and development expenses incurred. For costs incurred and revenues generated from third parties where the Company is deemed to be the principal participant, such as the BARDA contract, it recognizes revenue and costs using the gross basis of accounting; otherwise it uses the net basis of accounting.

Revenue for collaborative research and development activities typically consists of fees for services, or payments when specific milestones are met and match underlying activities occurring during the term of the arrangement.

For milestones that are deemed substantive, the Company recognizes the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to activities already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Foreign Currency

Functional and reporting currency

Items included in the Company’s consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, referred to as the functional currency. The Company operates in several jurisdictions with functional currencies of the U.S. dollar, the Australian dollar, and U.K. Sterling. The consolidated financial statements are presented in U.S. dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the related transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, as well as from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, are recognized in the consolidated statements of operations.

The results and financial position of any operations that have a functional currency different from the U.S. dollar are translated into U.S. dollar amounts. Assets and liabilities are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at average rates for period.

All resulting exchange differences are recognized as accumulated other comprehensive income, a separate component of stockholders’ equity.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recorded in stockholders’ equity as part of accumulated comprehensive income, net of related taxes.

Patent and License Expense

Legal fees incurred for patent application costs have been charged to expense and reported in research and development expense. Legal fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents and reported in research and development expense.

Share-Based Compensation Expense

Share-based compensation expense related to stock options is determined at the grant date using an option pricing model based on the closing price of the Company’s common stock on that date. The value of the award that is ultimately expected to vest is recognized as an expense on a straight-line basis over the employee's requisite service period.

Net Income (Loss) per Share

Basic and diluted income (loss) per share has been computed based on net income (loss) and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and warrants) are excluded from the calculation of diluted net loss per share as their inclusion would be anti-dilutive. The Company has excluded all options to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

The following table sets forth the computation of historical basic and diluted net income (loss) per share.

	Three Months Ended December 31,					Six Months Ended December 31,
	2012		2011			2012			2011

Income (loss) (in thousands)	$	4,829	$	(7,055	)	$	(2,413	)	$	(11,252	)
Weighted average shares outstanding		28,137,346		181,627,507			28,137,346			181,627,507
Weighted average shares outstanding adjusted using exchange ratio (Note 7) used to compute basic earnings per share		28,137,346		22,695,081			28,137,346			22,695,081
Dilutive effect of restricted stock and stock options		214,983		-			-			-
Shares used to compute diluted earnings per share		28,352,329		22,695,081			28,137,346			22,695,081
Basic income (loss) per share	$	0.17	$	(0.31	)	$	(0.09	)	$	(0.50	)
Diluted income (loss) per share	$	0.17	$	(0.31	)	$	(0.09	)	$	(0.50	)
Diluted shares excluded in the calculation of diluted income (loss)		-		-			214,983			-

Total Comprehensive Income

Comprehensive income is defined as the total change in stockholders’ equity during the period other than from transactions with stockholders, and for the Company, includes net income and cumulative translation foreign currency adjustments.

Segment Information

The Company currently reviews its business from a divisional perspective. All research and development activities relate to various anti-infective drug discovery and clinical development activities. Recently appointed senior management has assessed that research and development activities represent one reportable business segment. The Company operates globally in developing its projects at its laboratories in Australia and England.

The business segment information provided to the strategic steering committee for the reportable segments for the six months ended December 31, 2012 and 2011 are set out in the table below (in thousands):

Divisions	Research and Development						Corporate						Intersegment elimination						Total
	2012			2011			2012			2011			2012			2011			2012			2011

External revenue	$	9,689		$	4,801		$	6,823		$	4,114		$	(4,662	)	$	(2,676	)	$	11,850		$	6,239
Intersegment revenue		-			-			(4,662	)		(2,676	)		4,662			2,676			-			-
Total segment revenue	$	9,689		$	4,801		$	2,161		$	1,438			-			-		$	11,850		$	6,239

EBITDA	$	(6,503	)	$	(13,091	)	$	6,473		$	1,124			-			-		$	(30	)	$	(11,967	)

Depreciation and amortization	$	845		$	842		$	697		$	675			-			-		$	1,542		$	1,517

Under recently appointed senior management, the Company is currently undertaking a thorough strategic, operational and financial review, the purpose of which is to determine how it will align and allocate its capital and human resources to its respective ongoing development programs in the future.

Note 3 - Share Based Compensation

6 Months Ended

Dec. 31, 2012

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(3) Share-Based Compensation

A summary of stock option grants outstanding as of December 31, 2012, and the related activity during the six months ended December 31, 2012 is presented below:

	Number of Options
Options	Biota Holdings Limited			Nabi			Biota Pharmaceuticals, Inc.

Outstanding at June 30, 2012		6,182,853			3,665,201
Granted		686,365			-
Exercised		(413,335	)		-
Forfeited		-			(20,000	)
Expired		(601	)		(591,485	)

		6,455,282			3,053,716
Adjustment for Consolidation of shares					(2,544,798	)
Vested and exercised upon merger		(6,455,282	)		-
Balance on November 8, 2012 (date of merger)		-			508,918

Post-merger transactions:
Granted		-			-			931,590

Outstanding at December 31, 2012		-			508,918			931,590

Exercisable at December 31, 2012		-			508,918			-

On November 8, 2012, and in connection with the merger and based upon stockholder approval, Nabi’s board of directors approved a 1:6 reverse stock split of existing Nabi shares, which reduced the number of shares of common stock reserved for outstanding stock options to 508,918. The exercise price of all outstanding stock options as of that date have been adjusted to reflect the reverse stock split and are now between $11.22 and $99.90 per share, with terms expiring from March 27, 2013 to January 3, 2019.

Biota Holdings Limited had outstanding stock options to purchase 6,455,282 shares of its common stock at September 30, 2012. Upon approval of the merger with Nabi by the Supreme Court of Victoria on October 26, 2012, all of these outstanding stock options vested, resulting in the issuance of 4,639,104 shares of common stock and the vesting of 1,816,178 shares held by Biota Holdings Limited for this purpose. The related expense of $1.1 million associated with the issuance of shares of common stock has been recognized in full as a general and administrative expense in the consolidated statement of operations.

On November 12, 2012, the Company granted options to purchase 931,590 shares of common stock at an exercise price of $4.07. The grant becomes exercisable in three equal installments on the first, second and third anniversary of the grant date. The options have a 10 year term. The Company estimated the fair value of each stock option on the date of grant, using the Black-Scholes option-pricing formula, to be $2.72 using the following key assumptions:

Expected Term: The expected term represents the period over which the share-based awards are expected to be outstanding based on the Company’s historical experience. The Company estimated an expected term of 5 years.

Risk-Free Interest Rate: The Company used a risk-free rate of 0.65%, based the risk-free interest rate used in the assumptions on the implied yield currently available on the U.S. Treasury zero-coupon issues with a remaining term equivalent to the stock option award’s expected term.

Expected volatility: The Company used an expected volatility factor of 83.84%, based on the historical price of its common stock over the most recent period commensurate with the expected term of the stock option award.

Expected Dividend Yield: The Company does not intend to pay cash dividends on common stock for the foreseeable future. Accordingly, it assumed a dividend yield of zero.

The Company amortizes share-based compensation expense over the option’s vesting period using the straight-line attribution approach. For the three and six months periods ended December 31, 2012, the Company recognized approximately $0.1 million of share-based compensation expense related to the issuance of stock option grants.

A summary of outstanding restricted stock awards as of December 31, 2012, and the related activity during the six month period ending December 31, 2012 is presented below:

	Number of Awards
Awards	Nabi			Biota Pharmaceuticals, Inc.

Unvested at June 30, 2012		196,254
Vested and shares issued		(196,254	)

Balance on November 8, 2012 (date of merger)		-

Post-merger transactions:
Granted		-			214,983

Outstanding at December 31, 2012	Nil				214,983

On November 12, 2012, the Company granted 214,983 of restricted stock awards with an average fair value of $4.07. The restricted shares vest over three equal installments upon 90 days, and on the first and second anniversaries of the grant date. For the three month and six month periods ended December 31, 2012, the Company recognized approximately $0.2 million of share-based compensation expense related to the issuance of restricted stock units. As of December 31, 2012, there was $3.1 million of unrecognized compensation expense related to unvested share-based compensation arrangements. This expense is expected to be recognized over the next two years as the restricted shares vest.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 4 - Income Taxes

6 Months Ended

Dec. 31, 2012

Income Tax Disclosure [Text Block]

(4) Income Taxes

The Company is subject to income tax in the U.S., Australia and the United Kingdom (U.K.). A reconciliation of the (benefit) provision for income taxes, with the amount computed by applying the statutory company tax rate of 35% to the income (loss) before income taxes for the three and six month periods ended December 31, 2012, are set out in the tables below (in thousands):

	Three Months Ended December 31,
	2012			2011


Income (loss) before income taxes	$	4,823		$	(7,519	)

Computed by applying standard income tax rate of 35%		1,688			(2,632	)
Differences in foreign tax rates to standard rate		(257	)		379
Non qualifying research and development expenditure		2,662			1,904
Non-assessable income:
Australian research and development credit		(1,561	)		-
UK research and development incentive		(949	)		-
Gain on merger		(3,015	)		-
Disallowed expenses (income):
Share-based compensation		512			11
Non-taxable amortization		144			(569	)
Other		(449	)		(23	)
State taxes, net of federal benefit		261			-
Change in valuation allowance		958			410
Income tax benefit	$	(6	)	$	(520	)

	Six Months Ended December 31,
	2012			2011


Loss before income taxes	$	(2,517	)	$	(11,902	)

Computed by applying standard income tax rate of 35%		(881	)		(4,166	)
Differences in foreign tax rates to standard rate		110			239
Non qualifying research & development expenditure		2,947			2,490
Non-assessable income:
Australian research and development credit		(1,561	)		-
UK research and development incentive		(523	)		-
Gain on merger		(3,015	)		-
Disallowed expenses (income):
Share-based compensation		568			134
Non-taxable amortization		2			(139	)
Other		(16	)		6
State taxes, net of federal benefits		261			-
Change in valuation allowance		2,004			786
Income tax benefit	$	(104	)	$	(650	)

Significant components of deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting and tax purposes. A valuation allowance has been established, as the Company has determined that the realization of such assets is not more likely than not.

As of December 31, 2012, the Company’s foreign subsidiaries have no positive accumulated earnings. As such, no federal or state income taxes have been provided on the losses of its foreign subsidiaries under ASC 740. If in the future there are positive earnings generated from the Company’s foreign subsidiaries, the Company will evaluate whether to record any applicable federal and state income taxes on such earnings.

As of December 31, 2012 the Company has accumulated gross U.S. net operating losses of $180 million, which expire at various dates through 2032, U.S. research and experimental tax credit carry forwards of approximately $13 million ($11.3 million, net of unrecognized tax benefit) that expire in varying amounts through 2026, and U.S. alternative minimum tax credit carry forwards of $0.9 million. As of December 31, 2012, the Company also has accumulated Australian tax losses of A$59 million and accumulated UK tax losses of STG19 million available for carry forward against future earnings, which under relevant tax laws do not expire but may not be available under certain circumstances. A full valuation allowance has been established against the tax losses in the U.S. due to the volatility of earnings and the potential unavailability of the losses in some circumstances, including changes in ownership due to U.S. tax rules. The application of these rules may result in a complete elimination of the use of these tax attributes in the future, or subject such tax attributes to an annual limitation that may result in income tax loss and credit carry forwards expiring before the Company is able to fully utilize them. The Company is in the process of conducting a study to determine the impact of these tax rules. As a valuation allowance against all of the Company’s U.S. net deferred tax assets and Australian and UK tax losses has been established there is no current impact on these consolidated financial statements as a result of the application of these tax provisions.

The assets not subject to a valuation allowance relate to temporary differences arising on Australian balance sheet amounts that are expected to reverse where sufficient Australian taxable income will be available to utilize them.

Uncertain Tax Positions

The Company is subject to income taxes in the U.S., various states, and several foreign jurisdictions. Significant judgment is required in evaluating the Company’s tax positions and determining the provision for income taxes. The Company has established reserves for tax-related uncertainties based on estimates of whether, and to the extent to which, additional taxes may be due. These reserves are established when the Company believes that certain positions might be challenged despite its belief that its tax return positions are fully supportable. The Company adjusts these reserves in light of changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.

The Company is subject to tax audits in all jurisdictions for which it files tax returns. Tax audits by their very nature are often complex and can require several years to complete. Under the tax statute of limitations application to the Internal Revenue Code (“IRC”), the Company is no longer subject to U.S. federal income tax examinations by the Internal Revenue Services (“IRS”) for years before 2008. However, because the Company is carrying forward income tax attributes, such as net operating losses and tax credits from 2002 and earlier tax years, these attributes can still be audited in the future when used on an income tax return filed. Tax attributes carried forward from 2002 and earlier tax years recently utilized in tax years for which the statute of limitations have not yet expired are also subject to audit. Under the statute of limitations applicable to most state income tax laws, the Company is no longer subject to state income tax examinations by tax authorities for years before 2008 in states in which we have filed income tax returns. Certain states may take the position that the Company is subject to income tax in such states even though the Company has not filed income tax returns in such states and, depending on the varying state income tax statutes and administrative practices, the statute of limitations in such states may extend to years before 2008. The Company began foreign operations in 1985. The Company is subject to foreign tax examinations by tax authorities for all years of operations.

The Company has an unrecognized U.S. tax benefit of $2.5 million as of December 31, 2012. Any potential interest and penalties on unrecognized tax benefits were not significant. Unrecognized tax benefits are shown as a reduction in net deferred tax assets in the accompanying consolidated balance sheets.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 5 - Research and Development Credit

6 Months Ended

Dec. 31, 2012

Research, Development, and Computer Software Disclosure [Text Block]

(5) Research and Development Credit

An application for a claim of $4.4 million was made by the Company’s subsidiary, Biota Holdings Limited, under the Australian Government’s Research and Development tax incentive when Biota Holdings Limited submitted its tax return for its fiscal year ended June 30, 2012. This amount was recorded as a contingent asset as of June 30, 2012. On November 7, 2012, Biota Holdings Limited received cash for this claim. Although the credit is administered by the Australian government, it is not linked to the level of taxable income and is effectively a government grant. As such, the Company obtained an immediate benefit and therefore, the entire amount has been recognized within non-operating income in the consolidated statement of operations for the three and six month periods ending December 31, 2012.

For the current fiscal year, the Company does not expect to receive a research and development credit as its revenue is expected to exceed the qualifying revenue threshold.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Audit and Accounting Guide (AAG)
-Number AAG-FGC
-Paragraph 56, 57
-IssueDate 2006-05-01
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 68
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 6 - Licences, Royalty Agreements and Collaborative Arrangements

6 Months Ended

Dec. 31, 2012

Collaborative Arrangement Disclosure [Text Block]

(6) Licenses, Royalty Collaborative and Contractual Arrangements

Royalty agreements

The Company entered into a royalty-bearing research and license agreement with GSK in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor (NI) marketed by GSK as RelenzaTM to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis and is entitled to receive royalty payments of 7% of GSK's annual net sales of RelenzaTM in the U.S., Europe, Japan and certain other countries as well as 10% of GSK's annual net sales of RelenzaTM in Australia, New Zealand, South Africa and Indonesia. Royalties earned by the Company under this agreement for the three month period ending December 31, 2012 and 2011, were $1.0 million and $(1.6) million, respectively, and royalties earned for the six month period ending December 31, 2012 and 2011 were $1.0 million and $0.7 million, respectively. Beginning in 2014, the patents on RelenzaTM will begin to expire in certain countries and are scheduled to fully expire in 2019.

The Company also generates royalty revenue from the sale of Inavir® in Japan, pursuant to a collaboration and license agreement that the Company entered into with Daiichi Sankyo related to the development and commercialization of second generation, long-acting NI’s ("LANI"), including laninamivir octanoate. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children, which Daiichi Sankyo markets as Inavir®. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir® in Japan. Royalties earned by the Company under this agreement for the three month periods ending December 31, 2012 and 2011, were $0.9 million and $0.5 million, respectively, and royalties earned for the six month periods ending December 31, 2012 and 2011 were $0.9 million and $0.7 million, respectively. Under the collaboration and license agreement, the Company and Daiichi Sankyo co-own the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any third party licenses outside of Japan, the specific terms of which have yet to be finalized. Patents on laninamivir octanoate in Japan generally expire in 2027.

Collaborative and contract arrangements

On March 31, 2011, the Company’s wholly owned subsidiary, Biota Scientific Management Pty Ltd., was awarded a contract by the U.S. Office of Biomedical Advanced Research and Development Authority (“BARDA”). BARDA is part of the U.S. Office of the Assistant Secretary for Preparedness and Response ("ASPR") within the U.S. Department of Health and Human Services ("HHS"). The BARDA contract is for the late-stage development of laninamivir octanoate on a cost-plus-fixed-fee basis, the total of which is not to exceed $231.2 million. Pursuant to the BARDA contract, reimbursable costs include, but are not limited to, those incurred by the Company for clinical development, scale-up, formulation and manufacture leading to the potential licensure of laninamivir octanoate by the FDA. The BARDA contract is designed to fund and provide the Company with technical and clinical data, and U.S. based manufacturing to support the filing of a U.S. new drug application ("NDA") with the FDA for laninamivir octanoate. The performance period of the BARDA contract commenced on March 31, 2011, and continues for five years.

The Company is considered an active participant in the BARDA contract, with exposure to significant risks and rewards of commercialization relating to the development of laninamivir octanoate. Therefore, revenues from the contract and costs associated with the contract are recorded and recognized on a gross basis in the consolidated statement of operations.

Revenue earned by the Company under the BARDA contract for the three month periods ending December 31, 2012 and 2011, were $7.9 million and $3.1 million, respectively, and revenue earned for the six month periods ending December 31, 2012 and 2011 were $9.2 million and $4.5 million, respectively. Revenue totaling $18.4 million has been recognized to-date pursuant to this contract.

Note 7 - Merger

6 Months Ended

Dec. 31, 2012

Business Combination Disclosure [Text Block]

(7) Merger

Summary

On April 22, 2012, Nabi and Biota Holdings Limited entered into a merger implementation agreement (the “Agreement”), which was subsequently amended on August 6, 2012 and further amended on September 17, 2012. Pursuant to the terms and subject to the conditions set forth in the Agreement, Biota Holdings Limited became a wholly owned subsidiary of Nabi on November 8, 2012. As outlined in Note 1, Nabi then changed its name to Biota Pharmaceuticals, Inc.

Reverse Stock Split

On November 8, 2012, as contemplated by the Agreement and as approved by Nabi’s stockholders and board of directors, Nabi filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to affect a reverse stock split of Nabi’s common stock at a ratio of 1:6. As a result of the reverse stock split, each six shares of Nabi common stock issued and outstanding immediately prior to the reverse stock split were automatically combined into and became one share of Nabi common stock. Also, as a result of the reverse stock split, the per share exercise price of, and the number of shares of common stock underlying, of Company stock options outstanding immediately prior to the reverse stock split were automatically proportionally adjusted based on the one-for-six split ratio in accordance with the terms of such options. The reverse stock split did not alter the par value of the Nabi common stock or modify any voting rights or other terms of the common stock. Following the reverse stock split, 0.5 million stock options remained outstanding.

Exchange Ratio

Upon completion of the merger, each outstanding share of Biota Holdings Limited ordinary shares converted into the right to receive 0.1249539870 shares of Nabi common stock as determined pursuant to the exchange ratio, as calculated pursuant to the terms of the Transaction Agreement, as amended. Pursuant to the various agreements, Biota Holdings Limited stockholders received shares in Nabi common stock representing approximately 83% of the outstanding combined stock of the resulting combined company. Nabi stockholders continued to own their existing Nabi common stock, which represented approximately 17% of the outstanding combined stock of the resulting combined company. The issued share capital upon completion of the merger comprised of the following:

	No. of Shares
Ex-Nabi stockholders		4,720,999
Ex-Biota Holdings Limited stockholders		23,416,347
Total		28,137,346

Purchase Consideration and Net Assets Acquired

Due to the fact that former Biota Holdings Limited stockholders held a majority of the ongoing voting interest in the Company upon completion of the merger, the merger has been accounted for as a ‘reverse merger’, whereby Biota Holdings Limited is treated as the acquirer for financial accounting purposes, with Nabi being treated as the acquired company. In addition, members of the Company’s management and board of directors are principally drawn from the Biota Holdings Limited business, and the majority of the ongoing business is related to the Biota Holdings Limited business.

The purchase consideration in a reverse merger is determined with reference to the value of equity that the accounting acquirer (in this case Biota Holdings Limited,) issues to the stockholders of the accounting acquiree (Nabi, in this case) to give them their interest in the combined entity. Further, as a result of the merger, stock options to purchase an aggregate of 0.5 million shares of Nabi common stock that were held by officers and directors of Nabi immediately vested (see Note 3 to the consolidated financial statements). The fair values of the Nabi outstanding stock options were determined using the Black-Scholes option pricing model with the following assumptions: a strike price range between $11.34 – $99.91; a volatility range between 78.79% – 99.62%; a risk-free interest rate range between 0.12% – 0.87%; and an expected life range of 0.3 – 6.1 years.

The purchase price, based on the price per share of the Company’s common stock as of the date of the merger is as follows:

Number of shares issued to Nabi stockholders		4,720,999
Fair value per share, using volume weighted share price on November 9, 2012	$	4.0168
Implied purchase consideration (in thousands)	$	18,963

Number of stock options outstanding to former Nabi employees		508,918
Fair value per option	$	0.456
Implied purchase consideration (in thousands)	$	232

Total implied purchase consideration (in thousands)	$	19,195

The net assets acquired consist of (in thousands):

Cash	$	32,687
Accrual for severance obligations and employee benefits		(4,977	)
Accounts payable		(694	)
Other liabilities		(16	)
Net cash received	$	27,000

Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	$	7,805

No purchase consideration has been allocated to the residual value of any of Nabi’s drug development programs, including NicVAX® or any next-generation nicotine vaccine, or the potential royalty of Phoslyra that was sold to a third party in 2006, due to the significant uncertainty associated with future cash flows from these assets.

Pursuant to the Agreement, Biota Holdings Limited received net cash of $27 million from Nabi, while Nabi stockholders received a proportion of the combined entity based on the Biota Holdings Limited share price upon completion of the merger. Movements in the Biota Holdings Limited share price and the U.S. and Australian dollar exchange rates between the date of the determination of the exchange ratio and the date of the completion of the merger, coupled with changes in the fair value of certain assets and liabilities, have resulted in the net assets acquired exceeding the calculated purchase consideration. The gain recorded on the merger of $7.8 million is recognized as non-operating income in the condensed consolidated statements of operations.

Acquisition-related Costs

Acquisition-related costs related to the merger, including adviser, investment banking, legal, accounting and various other costs of $1.3 million and $4.6 million have been included as a general and administrative expense for the three and six month periods ended December 31, 2012, respectively. Total acquisition-related costs were approximately $6.5 million.

Pro forma Financial Information

The following table presents selected unaudited financial information, as if the merger with Nabi had occurred on July 1, 2011 (in thousands, expect per share data).

	Three Months Ended December 31,						Six Months Ended December 31,
	2012			2011			2012			2011

Pro forma net revenue	$	1,018		$	2,984		$	13,114		$	8,160
Pro forma net loss	$	(1,124	)	$	(8,989	)	$	(10,898	)	$	(13,164	)
Pro forma basic loss per share	$	(0.03	)	$	(0.31	)	$	(0.38	)	$	(0.46	)
Pro forma diluted loss per share	$	(0.03	)	$	(0.31	)	$	(0.38	)	$	(0.46	)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 8 - Commitments and Contingencies

6 Months Ended

Dec. 31, 2012

Commitments and Contingencies Disclosure [Text Block]

(8) Commitments and contingencies

Government Contracts and Research Grants

Revenue for services performed pursuant to government contracts is recognized when earned, typically when the underlying services or activities are rendered. Invoices are generally submitted monthly. The accuracy and appropriateness of costs charged to government contracts are subject to regulation, audit and possible disallowance by government agencies. Accordingly, costs billed or billable to government customers are subject to potential adjustment upon audit by such agencies.

Grant funding is initially recognized as deferred income and then recorded as revenue to match the costs that they are intended to compensate for. Revenue recognized in relation to these grants was $0.6 million and $0.8 million for the three and six month periods ended December 31, 2012, and $0.1 million and $0.3 million for the three and six month periods ended December 31, 2011, respectively.

Changes in government policies, priorities or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely affect the Company’s financial condition or results of operations if such changes negatively impacted our contract with BARDA. Furthermore, contracts with the U.S. government may be terminated or suspended by the U.S. government at any time, with or without cause. Such contract suspensions or terminations could result in expenses or charges not being reimbursed, or otherwise adversely affect the Company’s financial condition and/or results of operations.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Accounting Policies, by Policy (Policies)

6 Months Ended

Dec. 31, 2012

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The period-end condensed consolidated balance sheet data were derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.

Consolidation, Policy [Policy Text Block]

Principles of Consolidation and Presentation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Standards

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less to be cash equivalents.

Investment, Policy [Policy Text Block]

Short-Term Investments

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk and Other Risks and Uncertainties

Derivatives, Policy [Policy Text Block]

Derivative Instruments and Hedging Activities

Derivative financial instruments

Cash flow hedges

Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]

Receivables

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangible Assets

Intangible assets generally consist of two elements:

Royalty prepayments

Computer software

Lease, Policy [Policy Text Block]

Leased Assets

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-lived Assets

Severance Obligations, Policy [Policy Text Block]

Severance Obligations and Employee Benefits

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expense

Income Tax, Policy [Policy Text Block]

Income Taxes

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency

Functional and reporting currency

Transactions and balances

All resulting exchange differences are recognized as accumulated other comprehensive income, a separate component of stockholders’ equity.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Patent and License Expense

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-Based Compensation Expense

Earnings Per Share, Policy [Policy Text Block]

Net Income (Loss) per Share

The following table sets forth the computation of historical basic and diluted net income (loss) per share.

	Three Months Ended December 31,					Six Months Ended December 31,
	2012		2011			2012			2011

Income (loss) (in thousands)	$	4,829	$	(7,055	)	$	(2,413	)	$	(11,252	)
Weighted average shares outstanding		28,137,346		181,627,507			28,137,346			181,627,507
Weighted average shares outstanding adjusted using exchange ratio (Note 7) used to compute basic earnings per share		28,137,346		22,695,081			28,137,346			22,695,081
Dilutive effect of restricted stock and stock options		214,983		-			-			-
Shares used to compute diluted earnings per share		28,352,329		22,695,081			28,137,346			22,695,081
Basic income (loss) per share	$	0.17	$	(0.31	)	$	(0.09	)	$	(0.50	)
Diluted income (loss) per share	$	0.17	$	(0.31	)	$	(0.09	)	$	(0.50	)
Diluted shares excluded in the calculation of diluted income (loss)		-		-			214,983			-

Comprehensive Income, Policy [Policy Text Block]

Total Comprehensive Income

Segment Reporting, Policy [Policy Text Block]

Segment Information

Divisions	Research and Development						Corporate						Intersegment elimination						Total
	2012			2011			2012			2011			2012			2011			2012			2011

External revenue	$	9,689		$	4,801		$	6,823		$	4,114		$	(4,662	)	$	(2,676	)	$	11,850		$	6,239
Intersegment revenue		-			-			(4,662	)		(2,676	)		4,662			2,676			-			-
Total segment revenue	$	9,689		$	4,801		$	2,161		$	1,438			-			-		$	11,850		$	6,239

EBITDA	$	(6,503	)	$	(13,091	)	$	6,473		$	1,124			-			-		$	(30	)	$	(11,967	)

Depreciation and amortization	$	845		$	842		$	697		$	675			-			-		$	1,542		$	1,517

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2012

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended December 31,					Six Months Ended December 31,
	2012		2011			2012			2011

Income (loss) (in thousands)	$	4,829	$	(7,055	)	$	(2,413	)	$	(11,252	)
Weighted average shares outstanding		28,137,346		181,627,507			28,137,346			181,627,507
Weighted average shares outstanding adjusted using exchange ratio (Note 7) used to compute basic earnings per share		28,137,346		22,695,081			28,137,346			22,695,081
Dilutive effect of restricted stock and stock options		214,983		-			-			-
Shares used to compute diluted earnings per share		28,352,329		22,695,081			28,137,346			22,695,081
Basic income (loss) per share	$	0.17	$	(0.31	)	$	(0.09	)	$	(0.50	)
Diluted income (loss) per share	$	0.17	$	(0.31	)	$	(0.09	)	$	(0.50	)
Diluted shares excluded in the calculation of diluted income (loss)		-		-			214,983			-

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Divisions	Research and Development						Corporate						Intersegment elimination						Total
	2012			2011			2012			2011			2012			2011			2012			2011

External revenue	$	9,689		$	4,801		$	6,823		$	4,114		$	(4,662	)	$	(2,676	)	$	11,850		$	6,239
Intersegment revenue		-			-			(4,662	)		(2,676	)		4,662			2,676			-			-
Total segment revenue	$	9,689		$	4,801		$	2,161		$	1,438			-			-		$	11,850		$	6,239

EBITDA	$	(6,503	)	$	(13,091	)	$	6,473		$	1,124			-			-		$	(30	)	$	(11,967	)

Depreciation and amortization	$	845		$	842		$	697		$	675			-			-		$	1,542		$	1,517

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Note 3 - Share Based Compensation (Tables)

6 Months Ended

Dec. 31, 2012

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Options
Options	Biota Holdings Limited			Nabi			Biota Pharmaceuticals, Inc.

Outstanding at June 30, 2012		6,182,853			3,665,201
Granted		686,365			-
Exercised		(413,335	)		-
Forfeited		-			(20,000	)
Expired		(601	)		(591,485	)

		6,455,282			3,053,716
Adjustment for Consolidation of shares					(2,544,798	)
Vested and exercised upon merger		(6,455,282	)		-
Balance on November 8, 2012 (date of merger)		-			508,918

Post-merger transactions:
Granted		-			-			931,590

Outstanding at December 31, 2012		-			508,918			931,590

Exercisable at December 31, 2012		-			508,918			-

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

	Number of Awards
Awards	Nabi			Biota Pharmaceuticals, Inc.

Unvested at June 30, 2012		196,254
Vested and shares issued		(196,254	)

Balance on November 8, 2012 (date of merger)		-

Post-merger transactions:
Granted		-			214,983

Outstanding at December 31, 2012	Nil				214,983

Note 4 - Income Taxes (Tables)

6 Months Ended

Dec. 31, 2012

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Three Months Ended December 31,
	2012			2011


Income (loss) before income taxes	$	4,823		$	(7,519	)

Computed by applying standard income tax rate of 35%		1,688			(2,632	)
Differences in foreign tax rates to standard rate		(257	)		379
Non qualifying research and development expenditure		2,662			1,904
Non-assessable income:
Australian research and development credit		(1,561	)		-
UK research and development incentive		(949	)		-
Gain on merger		(3,015	)		-
Disallowed expenses (income):
Share-based compensation		512			11
Non-taxable amortization		144			(569	)
Other		(449	)		(23	)
State taxes, net of federal benefit		261			-
Change in valuation allowance		958			410
Income tax benefit	$	(6	)	$	(520	)

	Six Months Ended December 31,
	2012			2011


Loss before income taxes	$	(2,517	)	$	(11,902	)

Computed by applying standard income tax rate of 35%		(881	)		(4,166	)
Differences in foreign tax rates to standard rate		110			239
Non qualifying research & development expenditure		2,947			2,490
Non-assessable income:
Australian research and development credit		(1,561	)		-
UK research and development incentive		(523	)		-
Gain on merger		(3,015	)		-
Disallowed expenses (income):
Share-based compensation		568			134
Non-taxable amortization		2			(139	)
Other		(16	)		6
State taxes, net of federal benefits		261			-
Change in valuation allowance		2,004			786
Income tax benefit	$	(104	)	$	(650	)

Note 7 - Merger (Tables)

6 Months Ended

Dec. 31, 2012

Schedule of Stockholders Equity [Table Text Block]

	No. of Shares
Ex-Nabi stockholders		4,720,999
Ex-Biota Holdings Limited stockholders		23,416,347
Total		28,137,346

Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]

Number of shares issued to Nabi stockholders		4,720,999
Fair value per share, using volume weighted share price on November 9, 2012	$	4.0168
Implied purchase consideration (in thousands)	$	18,963

Number of stock options outstanding to former Nabi employees		508,918
Fair value per option	$	0.456
Implied purchase consideration (in thousands)	$	232

Total implied purchase consideration (in thousands)	$	19,195

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Cash	$	32,687
Accrual for severance obligations and employee benefits		(4,977	)
Accounts payable		(694	)
Other liabilities		(16	)
Net cash received	$	27,000

Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	$	7,805

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended December 31,						Six Months Ended December 31,
	2012			2011			2012			2011

Pro forma net revenue	$	1,018		$	2,984		$	13,114		$	8,160
Pro forma net loss	$	(1,124	)	$	(8,989	)	$	(10,898	)	$	(13,164	)
Pro forma basic loss per share	$	(0.03	)	$	(0.31	)	$	(0.38	)	$	(0.46	)
Pro forma diluted loss per share	$	(0.03	)	$	(0.31	)	$	(0.38	)	$	(0.46	)

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References + Details

Note 1 - Company Overview (Detail) $ in Millions	6 Months Ended
Note 1 - Company Overview (Detail) $ in Millions	Dec. 31, 2012 USD ($)
Biota
Ownership Percentage	83.00%
Nabi
Ownership Percentage	17.00%
Contractual Obligation (in Dollars)	$ 231
Net closing cash balance (in Dollars)	$ 27

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Detail) $ in Thousands	6 Months Ended
	Dec. 31, 2012 USD ($)
Nabi Officers and Employees [Member]
Severance Obligations Accrued (in Dollars)	$ 5,000
Maturity Up To 90 Days
Maturity Time of Liquid Investments	90 days
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Finite-Lived Intangible Asset, Useful Life	1 year
Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years
Finite-Lived Intangible Asset, Useful Life	3 years
Severance Obligations Accrued (in Dollars)	$ 4,423
Number of Reportable Segments	1

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Detail) - Historical Basic and Diluted Net Income (Loss) Per Share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
Pre Adjustment Using Exchange Ratio [Member]
Weighted average shares outstanding	28,137,346	181,627,507	28,137,346	181,627,507
Adjusted Using Exchange Ratio [Member]
Weighted average shares outstanding	28,137,346	22,695,081	28,137,346	22,695,081
Basic income (loss) per share (in Dollars per share)	$ 0.17	$ (0.31)	$ (0.09)	$ (0.50)
Diluted income (loss) per share (in Dollars per share)	$ 0.17	$ (0.31)	$ (0.09)	$ (0.50)
Earnings Per Share, Diluted [Member]
Shares used to compute diluted earnings per share	28,352,329	22,695,081	28,137,346	22,695,081
Income (loss) (in thousands) (in Dollars)	$ 4,829	$ (7,055)	$ (2,413)	$ (11,252)
Weighted average shares outstanding	28,137,346	22,695,081	28,137,346	22,695,081
Dilutive effect of restricted stock and stock options (in Dollars)	$ 214,983
Shares used to compute diluted earnings per share	28,352,329	22,695,081	28,137,346	22,695,081
Basic income (loss) per share (in Dollars per share)	$ 0.17	$ (0.31)	$ (0.09)	$ (0.50)
Diluted income (loss) per share (in Dollars per share)	$ 0.17	$ (0.31)	$ (0.09)	$ (0.50)
Diluted shares excluded in the calculation of diluted income (loss)			214,983

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Detail) - Business Segment Information - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
Research and Development [Member]
External revenue			$ 9,689	$ 4,801
Total segment revenue			9,689	4,801
EBITDA			(6,503)	(13,091)
Depreciation and amortization			845	842
Corporate [Member]
External revenue			6,823	4,114
Intersegment revenue			(4,662)	(2,676)
Total segment revenue			2,161	1,438
EBITDA			6,473	1,124
Depreciation and amortization			697	675
Intersegment Elimination [Member]
External revenue			(4,662)	(2,676)
Intersegment revenue			4,662	2,676
Reportable Segment [Member]
External revenue			11,850	6,239
Total segment revenue			11,850	6,239
EBITDA			(30)	(11,967)
Depreciation and amortization			1,542	1,517
EBITDA	$ 4,823	$ (7,575)	$ (2,517)	$ (11,902)

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References + Details

Note 3 - Share Based Compensation (Detail) - USD ($)		1 Months Ended			2 Months Ended	3 Months Ended		6 Months Ended
Note 3 - Share Based Compensation (Detail) - USD ($)	Nov. 08, 2012	Nov. 30, 2012	Oct. 26, 2012	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 12, 2012	Jun. 30, 2012	Jun. 30, 2011
Stock Options [Member]
Allocated Share-based Compensation Expense (in Dollars)									$ 100,000
Restricted Stock [Member]
Allocated Share-based Compensation Expense (in Dollars)									$ 200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		214,983
Common Stock [Member]
Common Stock, Shares, Issued					34,219,690	34,219,690	181,703,711		34,219,690	181,703,711		182,350,316	181,417,556
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)			1,816,178		4,639,104	4,639,104			4,639,104
General and Administrative Expense (in Dollars)			$ 1,100,000
Two Year Amortization Period [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized (in Dollars)					$ 3,100,000	$ 3,100,000			$ 3,100,000
Minimum [Member] \| Nabi
Investment Options, Exercise Price (in Dollars per share)									$ 11.22
Maximum [Member] \| Nabi
Investment Options, Exercise Price (in Dollars per share)									$ 99.90
Pre Merger
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									508,918
Nabi
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)					500,000	500,000			500,000
Biota
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		931,590		6,455,282
Investment Options, Exercise Price (in Dollars per share)		$ 4.07
Estimate of Fair Value, Fair Value Disclosure [Member]
Share Price (in Dollars per share)											$ 2.72
Stockholders' Equity, Reverse Stock Split	1:6	1:6
Common Stock, Shares, Issued			4,639,104		34,219,690	34,219,690			34,219,690			182,350,316
General and Administrative Expense (in Dollars)						$ 7,077,000	$ 1,853,000		$ 10,268,000	$ 3,651,000
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term									5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate									0.65%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate									83.84%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate									0.00%
Restricted Investments, at Fair Value (in Dollars)											$ 4.07
Share-Based Compensation Restricted Stock Number of Installments									3
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								90 days	90 days

Note 3 - Share Based Compensation (Detail) - Summary of Option Activity Under Stock Compensation Plans - shares	6 Months Ended
	Dec. 31, 2012	Nov. 08, 2012	Jun. 30, 2012
Biota Holdings Limited \| Pre Merger
Balance Outstanding		6,455,282
Post-merger transactions:
Granted	686,365
Biota Holdings Limited
Balance Outstanding			6,182,853
Post-merger transactions:
Vested and exercised upon merger		(6,455,282)
Exercised	(413,335)
Expired	(601)
Nabi \| Pre Merger
Balance Outstanding		3,053,716
Nabi \| Post Merger
Balance Outstanding		508,918
Nabi
Balance Outstanding	508,918		3,665,201
Exercisable at December 31, 2012	508,918
Post-merger transactions:
Adjustment for Consolidation of shares		(2,544,798)
Forfeited	(20,000)
Expired	(591,485)
Post Merger
Post-merger transactions:
Granted	931,590
Balance Outstanding	931,590

Note 3 - Share Based Compensation (Detail) - Summary of Restricted Stock Awards - shares	6 Months Ended
	Dec. 31, 2012	Jun. 30, 2012
Nabi
Unvested at June 30, 2012		196,254
Vested and shares issued	(196,254)
Biota
Post-merger transactions:
Granted	214,983
Outstanding at December 31, 2012	214,983

Note 4 - Income Taxes (Detail) - 6 months ended Dec. 31, 2012 £ in Millions, $ in Millions, $ in Millions	USD ($)	AUD ($)	GBP (£)
United States of America
Operating Loss Carryforwards	$ 180.0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	35.00%
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 13.0
Deferred Tax Assets, Tax Credit Carryforwards	11.3
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	0.9
Deferred Tax Assets, Operating Loss Carryforwards (in Pounds and Dollars)		$ 59	£ 19
Unrecognized Tax Benefits	$ 2.5

Note 4 - Income Taxes (Detail) - Reconciliation of the (Benefit)/Provision for Income Taxes - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
Stock Based Payment [Member]
Disallowed expenses (income):
Share-based compensation	$ 512	$ 11	$ 568	$ 134
Australia
Non-assessable income:
Research & Development Incentive/Credit	(1,561)		(1,561)
UK Research and Development Incentive
Non-assessable income:
Research & Development Incentive/Credit	(949)		(523)
Gain on merger	(3,015)		(3,015)
Income (loss) before income taxes	4,823	(7,519)	(2,517)	(11,902)
Computed by applying standard income tax rate of 35%	1,688	(2,632)	(881)	(4,166)
Differences in foreign tax rates to standard rate	(257)	379	110	239
Non qualifying research and development expenditure	2,662	1,904	2,947	2,490
Disallowed expenses (income):
Non-taxable amortization	144	(569)	2	(139)
Other	(449)	(23)	(16)	6
State taxes, net of federal benefit	261		261
Change in valuation allowance	958	410	2,004	786
Income tax benefit	$ (6)	$ (520)	$ (104)	$ (650)

Note 5 - Research and Development Credit (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2012	Jun. 30, 2012
Research and Development Credit	$ 4,428	$ 4,428	$ 4,400

Note 6 - Licences, Royalty Agreements and Collaborative Arrangements (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		21 Months Ended
	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Major Countries \| GSK
Royalty Payment Percentage				7.00%
Australia, New Zealand, South Africa and Indonesia \| GSK
Royalty Payment Percentage				10.00%
GSK
Royalty Revenue		$ 1,000	$ (1,600)	$ 1,000	$ 700
Daiichi Sankyo
Royalty Payment Percentage				4.00%
Royalty Revenue		900	500	$ 900	700
BARDA
Contracts Revenue		7,900	3,100	9,200	$ 4,500	$ 18,400
Contract Term					5 years
Royalty Revenue		$ 1,943	$ (1,047)	$ 1,927	$ 1,460
Contracts Revenue	$ 231,200

Note 7 - Merger (Detail) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	3 Months Ended	6 Months Ended
	Nov. 08, 2012	Nov. 30, 2012	Dec. 31, 2012	Dec. 31, 2012
General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs (in Dollars)			$ 1.3	$ 4.6
Minimum [Member] \| Nabi
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price (in Dollars per share)			$ 11.34	$ 11.34
Fair Value Assumptions, Expected Volatility Rate				78.79%
Fair Value Assumptions, Risk Free Interest Rate				0.12%
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term				109 days
Maximum [Member] \| Nabi
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price (in Dollars per share)			$ 99.91	$ 99.91
Fair Value Assumptions, Expected Volatility Rate				99.62%
Fair Value Assumptions, Risk Free Interest Rate				0.87%
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term				6 years 36 days
Nabi
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)			500,000	500,000
Business Acquisition, Percentage of Voting Interests Acquired			17.00%	17.00%
Biota Holdings Limited
Business Acquisition, Percentage of Voting Interests Acquired			83.00%	83.00%
Stockholders' Equity, Reverse Stock Split	1:6	1:6
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)				0.1249539870
Cash Acquired from Acquisition, Net (in Dollars)				$ 27.0
Business Combination, Bargain Purchase, Gain Recognized, Amount (in Dollars)				7.8
Business Combination, Acquisition Related Costs (in Dollars)				$ 6.5

Note 7 - Merger (Detail) - Issued Share Capital	Dec. 31, 2012 shares
Nabi
Number of Shares on Issue	4,720,999
Biota Holdings Limited
Number of Shares on Issue	23,416,347
Number of Shares on Issue	28,137,346

Note 7 - Merger (Detail) - Fair Value Purchase Consideration - Nabi $ / shares in Units, $ in Thousands	6 Months Ended
	Dec. 31, 2012 USD ($) $ / shares shares
Stock Options [Member]
Fair Value Purchase Consideration	$ 232
Stock Shares
Fair Value Purchase Consideration	$ 18,963
Number of shares issued to Nabi stockholders (in Shares) \| shares	4,720,999
Fair value per share, using volume weighted share price on November 9, 2012 (in Dollars per share) \| $ / shares	$ 4.0168
Fair Value Purchase Consideration	$ 19,195
Number of stock options outstanding to former Nabi employees (in Shares) \| shares	508,918
Fair value per option (in Dollars per share) \| $ / shares	$ 0.456

- Definition

Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910684&loc=d3e4570-128470

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=18499824&loc=d3e4237-128469

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=18499824&loc=d3e4243-128469

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 40
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910732&loc=d3e4805-128471

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3642-128468

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 27
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3629-128468

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(3),(c)(1)
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 7 - Merger (Detail) - Net Assets Acquired $ in Thousands	6 Months Ended
	Dec. 31, 2012 USD ($)
Biota
Cash	$ 32,687
Accrual for severance obligations and employee benefits	(4,977)
Accounts payable	(694)
Other liabilities	(16)
Net cash received	27,000
Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	7,805
Cash	32,687
Net cash received	$ 27,000

Note 7 - Merger (Detail) - Business Acquisition Pro Forma Information - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
Pro forma net revenue (in Dollars)	$ 1,018	$ 2,984	$ 13,114	$ 8,160
Pro forma net loss (in Dollars)	$ (1,124)	$ (8,989)	$ (10,898)	$ (13,164)
Pro forma basic loss per share	$ (0.03)	$ (0.31)	$ (0.38)	$ (0.46)
Pro forma diluted loss per share	$ (0.03)	$ (0.31)	$ (0.38)	$ (0.46)

- Definition

The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

+ References + Details

- Definition

The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

+ References + Details

Note 8 - Commitments and Contingencies (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
Deferred Revenue, Revenue Recognized	$ 0.6	$ 0.1	$ 0.8	$ 0.3